SWX:SANN

Santhera Publishes Agenda for its Annual General MeetingSanthera Publishes Agenda for its Annual General Meeting

Santhera Publishes Agenda for its Annual General Meeting

Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM),…

3 weeks ago
Santhera Full Year Results for the Year Ended 31 December 2024Santhera Full Year Results for the Year Ended 31 December 2024

Santhera Full Year Results for the Year Ended 31 December 2024

Transformational year following the successful launch of AGAMREE® Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces…

3 weeks ago
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS ScotlandSanthera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland

Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in…

4 months ago